Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595597 | 0.83 | HTR2A (0.50) | HTR2ABCHEACHE | |
| SCHEMBL5019354 | 0.83 | HTR2A (0.50) | HTR2ABCHEACHE | |
| SCHEMBL7857614 | 0.80 | HTR2A (0.51) | HTR2A | |
| SCHEMBL7502205 | 0.79 | HTR2A (0.51) | HTR2A | |
| SCHEMBL7507759 | 0.79 | HTR2A (0.46) | HTR2AKMT2AMEN1BCHEMAPT | |
| SCHEMBL7505117 | 0.78 | HTR2A (0.45) | HTR2A | |
| SCHEMBL7508785 | 0.77 | CNR1 (0.53) | HTR2AKMT2AMEN1 | |
| SCHEMBL7506422 | 0.77 | HTR2A (0.44) | HTR2A | |
| SCHEMBL6923878 | 0.76 | MAOA (0.59) | BCHEACHE | |
| SCHEMBL2153529 | 0.76 | KCNH2 (0.45) | KMT2AMEN1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908947-B2 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20020072514-A1 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | HOECHST AKTIENGESELLSCHAFT | 2002-06-13 | — | — | US | disclosed |
| US-6333349-B1 | POTASSIUM CHANNEL OR THE I.SUB.KS CHANNEL OPENED BY CYCLIC ADENOSINE MONOPHOSPHATE AS POTASSIUM CHANNEL ACTIVATORS AND CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL REGION OR FOR THE TREATMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| US-6184221-B1 | ANTIARRHYTHMIA AGENTS, ANTIULCER AGENTS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2001-02-06 | — | — | US | disclosed |
| US-6177449-B1 | CARDIOVASCULAR DISORDERS; ANTIULCER AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6087399-A | ANTIULCER AGENTS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-07-11 | — | — | US | disclosed |
| US-6071953-A | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-06 | — | — | US | disclosed |
| US-6015822-A | ANTIULCER, ANTIDIARRHEA, AND ANTIARRHYTHMIA AGENTS; CARDIOVASCULAR AND GASTROINTESTINAL DISORDERS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-01-18 | — | — | US | disclosed |
| US-6008245-A | TREATMENT OF PROPHYLAXIS AND CARDIOVASCULAR DISORDERS, IN PARTICULAR ARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL DISORDERS, DIARRHEAL DISEASES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 1999-12-28 | — | — | US | disclosed |
| US-5955607-A | TREATING CARDIOVASCULAR AND GASTROINTESTINAL DISORDERS | HOECHST MARION ROUSSEL DEUTSCHLAND (DE) | 1999-09-21 | — | — | US | disclosed |
| US-5856338-A | Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparation comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | disclosed |
| WO-1998037083-A1 | SULPHONAMIDE-SUBSTITUTED THIOPHENES AND A METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT, AS WELL AS A MEDICAMENT CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
| EP-0860440-A1 | Sulfonamido substituted chromane derivatives with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| EP-0857724-A1 | Sulfonamide substituted compounds, process for their preparation, their use as medicine or for diagnostic purpose | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072514-A1 | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them | KCNN3, KCNJ1, KCNJ11 | HTR2A 2587/4885KMT2A 2568/4885MEN1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.